

AFSSI PREMIER PÔLE
DE RECHERCHE
& DÉVELOPPEMENT
PRÉCLINIQUE
EN FRANCE
PILIER DE L'INNOVATION



LES ENTREPRISES
PARTENAIRES DE VOTRE R&D

afssi.fr

Les membres **AFSSI**
ont la **parole**

WEBINAIRE

 **oxeltis**

Faire de la France le leader de la R&D en santé



- Oxeltis: Your Partner in Medicinal Chemistry and Life Sciences R&D



Stéphane Salamone
Oxeltis

04 99 235 036

Montpellier

salamone.stephane@oxeltis.com

www.oxeltis.com



NOTRE ACTIVITÉ

Oxeltis apporte un service de chimie médicinale pour la conception de nouvelles molécules d'intérêt thérapeutique.

Oxeltis réalise également des synthèses à façon du mg à plusieurs dizaines de grammes, et propose un service de route scouting et d'optimisation de voies de synthèses dans le cadre d'une première montée d'échelle



Oxeltis

- 600 m² de laboratoires, 46 sorbonnes
- 21 chimistes dont 4 chefs de projets
- Equipe hautement qualifiée (PhD/MSc 1:1)
Formations internes/externes
- Equipe dédiée client
- >80% CA à l'export (US, EU)
Big pharma, biotechs, SATT



Jean-Marc ALLAIRE
Co-founder & CEO



Stéphane SALAMONE
Chemistry Director



Olivier LAVERGNE
Chem4LS CEO



Patrick TROUILLEUX
IC2D CEO



Marie HAMANN
Team management



Franck GALLIER
Team management



Marc LAMBLIN
Team management




Guillaume LACONDE
Team management


Techniques vertes / innovantes



Microwave
Biotage
initiator+



Mechanochem
MM400




Flow & Photochem
PR160 kit
(440; 390 & 525nm)



- Qualité de service: ISO 9001 en cours
- Focus HSE (SOP, audit externe, équipements)
- Protection des données garantie (serveur sécurisé, cahier de laboratoire électronique, cloud)

Qualité analytique

- ❑ Equipement analytique : 3 LC/MS (DAD, DEDL), 6 flash systems, prep HPLC, Xbridge Prep C18, XSelect HSS T3, Chiralpak IH.



Agilent
LC-MS



Interchim Puriflash
DAD + ELSD




Gilson-GX-271

- ❑ Accès local à diverses ressources analytiques. (RMN (C, H, P, N, F) 400-600 MHz,) IR, MALDI, XRD.


Nucleosides

- ❑ Hallmark of Oxeltis core expertise
- ❑ 50% of the activity
- ❑ >1200 final compounds to date





Peptides

- ❑ Semi-automated solid phase platform
- ❑ Up to 15-20 amino acids chain, linear or stapled




PROTACs

- ❑ POI Ligands – Small molecule
- ❑ Linkers
- ❑ CRBN and VHL Ligands – “In house” library
- ❑ Negative Control




Nucleosides

- Hallmark of Oxeltis core expertise
- 50% of the activity
- >1200 final compounds to date





Peptides

- Semi-automated solid phase platform
- Up to 15-20 amino acids chain, linear or stapled




PROTACs

- POI Ligands – Small molecule
- Linkers
- CRBN and VHL Ligands – “In house” library
- Negative Control




Heterocycles

- Large variety of highly functionalized moieties
- N, O, S, P, B, Si, etc...




Macrocycles

- 8-18 membered rings




Steroids

- Highly functionalized



Carbohydrates

- Sugar derivatives, oligosaccharides, reference compounds
- Glucosides, metabolites





5 points clés à retenir

- Equipe d'experts
- Techniques innovantes
- Rapidité, flexibilité
- Engagement qualité
- Confidentialité assurée

